DEB-TACE With Visualable Microspheres Versus PVA Microspheres for HCC

Inclusion Criteria:

• CNLC Ia-IIIa HCC patients who require transarterial chemoembolization (TACE) and arenot suitable for or refuse surgical resection, liver transplantation, or ablationLiver function classification of Child-Pugh A or B
• ECOG PS score of 0-2
• With measurable lesions that had not been embolized (if there are more than 3 lesions,select the three largest lesions as target lesions, and the maximum diameter of targetlesion is ≤10cm)
• Agree to participate in this trial and voluntarily sign the informed consent form

Exclusion Criteria:

• Target lesions were embolized, or will require concomitant ablation or radiotherapyafter TACE treatment(s)
• With diffuse liver tumor or extrahepatic metastasis, expected survival <6 months Withsepsis or multiple organ dysfunction
• Severe liver dysfunction (Child-Pugh C) , or severerenal dysfunction (blood creatinine >2 mg/dL)
• Significant reductions in white blood cells or platelets (white blood cells <3.0×10^9/L, platelets <50×10^9/L, hemoglobin<60g/L) that cannot be corrected (exceptsplenomegaly or chemotherapy-induced bone marrow suppression) Uncorrectablecoagulation dysfunction (PT prolonged by >3 seconds above the upper limit of normal)
• With severe infection (>5 times the upper limit of normal white blood cells) The mainportal vein was completely embolized by tumor thrombus without collateral blood supply
• With risk of ectopic embolization (uncorrected arteriovenous fistula or portal venousfistula) in the target lesion supplying arteries
• Angiography shows vascular anatomy obstruction or vasospasm that will affect thecatheter placemenr embolic agent injection
• Known allergy to iodine-containing contrast agents, polyvinyl alcohol materials oranthracycline t ochemotherapy drugs
• Pregnant or lactating women
• Patients who are participating in other trial(s)
• Unsuitable for participation in this trial deemed by the researchers